Antifungals in medicine and agriculture
Dear Friends of the Atlas,
A major issue in medical mycology today is emerging resistance to antifungals that interferes with optimal therapy of seriously ill patients. Whether the situation will be similarly dramatic as with multidrug-resistant bacterial infections is under discussion (Hof, 2026), but obviously there is a problem. Two types of resistance are noted, of which acquired resistance in Aspergillus fumigatus is the best known and widely studied. Today, 10−15% of A. fumigatus strains in many countries are resistant to the commonly used azoles in the hospital for the management of pulmonary aspergillosis (Song et al., 2025). Soon after its discovery in The Netherlands (Snelders et al., 2009), it was realized that the origin of this fungal evolution lies in agriculture. Composted plant debris in tulip farming appears to be a main habitat for the sexual state of the fungus (Zhang et al., 2022), which goes through rapid adaptation under the pressure of the massive use of azoles that are closely akin to the ones used in medicine; see the very informative paper of Muller et al. (2026). This is done to keep the vulnerable tulips free from fungal diseases, but is untenable in the long run. A similar problem is emerging in a newly discovered antifungal class, orotomides, where medical application may be jeopardized by agricultural fungicides with the same target as orolofim (van Rhijn et al., 2024), potentially leading to cross-resistance in Aspergillus fumigatus.
The connection of cause and effect in different areas of our society are recognized since recently under the ‘One Health’ concept. Since this idea is becoming mainstream, such connections are revealed everywhere. A comprehensive article was recently published (Roohi et al., 2026) explaining the numerous consequences of thoughtless use of agricultural fungicides.
A different form of emerging antifungal resistance is now being observed among dermatophytes. Trichophyton indotineae, a lineage in the T. mentagrophytes complex is spreading globally from South Asia and Iran and has now been reported from 28 countries (Dos Santos et al., 2025). In addition to frequent terbinafine resistance, and often also azole resistance, this fungus is highly virulent causing extensive skin lesions (Bishoi et al., 2018). It was formerly known as ‘ITS genotype VIII’ in the T. mentagrophytes complex. Remarkably, also a ‘genotype VII’ is emerging, with similar high virulence but a somewhat more restricted host range (Lapa et al., 2025). The origin of resistance in dermatophytes is entirely different from that of Aspergillus: here the patients themselves are to blame by the irrational use of antifungal creams, often combined with steroids (Bristow & Joshi, 2023). Rapid recognition of the culprit directly in clinical specimens is now possible using species-specific molecular assay based on a genomic marker (Tang et al., 2026).
Last April, a successful meeting about One Health was held at the Westerdijk Institute in The Netherlands, and another one will be organized 22−25 September in Innsbruck, Austria, see info here. Reports and abstracts of both meetings will be published in the journal One Health Mycology. Medical and environmental problems will also be discussed in the meeting on Black Yeast-like Fungi 22−23 October in Barcelona, Spain, see here.
References:

